NANEXA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.606 SEK | -5.31% |
|
-8.46% | -50.73% |
| Apr. 16 | Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed | CI |
| Mar. 08 | Transcript : Nanexa AB - Special Call |
| Sales 2024 * | 71.3M 6.52M | Sales 2025 * | 69.5M 6.35M | Capitalization | 82.23M 7.52M |
|---|---|---|---|---|---|
| Net income 2024 * | 16M 1.46M | Net income 2025 * | -4M -366K | EV / Sales 2024 * | 0.23 x |
| Net cash position 2024 * | 65.5M 5.99M | Net cash position 2025 * | 82M 7.5M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
15.2
x | P/E ratio 2025 * |
2.75
x | Employees | 19 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Nanexa AB
More press releases
| 1 day | -5.31% | ||
| 1 week | -8.46% | ||
| Current month | -21.91% | ||
| 1 month | -20.26% | ||
| 3 months | -44.40% | ||
| 6 months | -38.79% | ||
| Current year | -50.73% |
1 week
0.60
0.67
1 month
0.600.89
Current year
0.601.45
1 year
0.603.94
3 years
0.6011.10
5 years
0.6015.40
10 years
0.6016.09
| Managers | Title | Age | Since |
|---|---|---|---|
Mårten Rooth
FOU | Founder | 47 | 06-12-31 |
Anders Johansson
FOU | Founder | 48 | 06-12-31 |
David Westberg
CEO | Chief Executive Officer | 64 | 15-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 75 | 20-06-01 | |
| Director/Board Member | 69 | 22-12-31 | |
| Corporate Officer/Principal | 62 | 14-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.606 | -5.31% | 449,411 |
| 24-04-25 | 0.64 | -0.62% | 262,901 |
| 24-04-24 | 0.644 | -3.01% | 255,817 |
| 24-04-23 | 0.664 | +3.75% | 17,042 |
| 24-04-22 | 0.64 | -3.32% | 729,113 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:29 am EDT
More quotes
Nanexa AB is a Sweden-based company engaged in the drug delivery systems industry. The Company specializes in the nanotechnology and research and development in life science. Its products portfolio is comprised of PharmaShell, a drug delivery system that allows for targeting and dosing of drugs; antifungal coating, a system that protects medical products from the in-growth of fungi; and low-friction coating for peripheral venous catheters.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -50.73% | 7.5M | |
| -10.84% | 187M |
- Stock Market
- Equities
- NANEXA Stock
